Sema4 Holdings Corp. Investors: November 7, 2022 Last Day to actively participate in the case. Please contact the Portnoy Law Firm to recover your losses
November 07, 2022 14:36 ET
|
Portnoy Law
LOS ANGELES, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors that a class action has been filed on...
Sema4 Holdings Corp. Investors: Please contact the Portnoy Law Firm to recover your losses; Last days to actively participate in the case; November 7, 2022
October 20, 2022 08:00 ET
|
Portnoy Law
LOS ANGELES, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors that a class action has been filed on...
Sema4 Holdings Corp. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
September 15, 2022 13:16 ET
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4”...
Sema4 Holdings Corp. Equity Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Sema4 Holdings Corp. (SMFR)
September 12, 2022 14:23 ET
|
Robbins LLP
SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that...
Sema4 to Participate at Two Investor Conferences in June 2022
May 26, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
May 02, 2022 07:45 ET
|
Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 26, 2022 16:05 ET
|
Sema4
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 Achieves HITRUST CSF Certification
April 06, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform,...
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
April 05, 2022 08:00 ET
|
Sema4
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the...